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Estrogen receptor variants in ER-positive basal-type breast
cancers responding to therapy like ER-negative breast cancers
Floris H. Groenendijk 1, Tina Treece2, Erin Yoder2, Paul Baron3, Peter Beitsch4, William Audeh2, Winand N. M. Dinjens1,
Rene Bernards 2,5 and Pat Whitworth6
Immunohistochemically ER-positive HER2-negative (ER+HER2−) breast cancers are classiﬁed clinically as Luminal-type. We showed
previously that molecular subtyping using the 80-gene signature (80-GS) reclassiﬁed a subset of ER+HER2− tumors to molecular
Basal-type. We report here that molecular reclassiﬁcation is associated with expression of dominant-negative ER variants and
evaluate response to neoadjuvant therapy and outcome in the prospective neoadjuvant NBRST study (NCT01479101). The 80-GS
reclassiﬁed 91 of 694 (13.1%) immunohistochemically Luminal-type tumors to molecular Basal-type. Importantly, all 91 discordant
tumors were classiﬁed as high-risk, whereas only 66.9% of ER+/Luminal-type tumors were classiﬁed at high-risk for disease
recurrence (i.e., Luminal B) (P < 0.001). ER variant mRNA (ERΔ3, ERΔ7, and ERα-36) analysis performed on 84 ER+/Basal tumors and
48 ER+/Luminal B control tumors revealed that total ER mRNA was signiﬁcantly lower in ER+/Basal tumors. The relative expression
of ERΔ7/total ER was signiﬁcantly higher in ER+/Basal tumors compared to ER+/Luminal B tumors (P < 0.001). ER+/Basal patients
had similar pathological complete response (pCR) rates following neoadjuvant chemotherapy as ER−/Basal patients (34.3 vs.
37.6%), and much higher than ER+/Luminal A or B patients (2.3 and 5.8%, respectively). Furthermore, 3-year distant metastasis-free
interval (DMFI) for ER+/Basal patients was 65.8%, signiﬁcantly lower than 96.3 and 88.9% for ER+/Luminal A and B patients,
respectively, (log-rank P < 0.001). Signiﬁcantly lower total ER mRNA and increased relative ERΔ7 dominant-negative variant
expression provides a rationale why ER+/Basal breast cancers are molecularly ER-negative. Identiﬁcation of this substantial subset
of patients is clinically relevant because of the higher pCR rate to neoadjuvant chemotherapy and correlation with clinical outcome.
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INTRODUCTION
Diagnostic testing of breast cancers for hormone receptor (HR)
and HER2 status by immunohistochemistry and/or in-situ hybri-
dization is routinely performed as an integral step to clinically
deﬁne tumor characteristics and predict tumor behavior.1,2
Advancement of technology has made it possible to molecularly
characterize these tumors at the genomic level by evaluating
underlying and intrinsic differences in tumor biology.3,4 Although
clinical subtypes overlap with these molecular subtypes, a
signiﬁcant number of patients will be reclassiﬁed based on the
functionality of molecular pathways.5,6 This reclassiﬁcation may
have important consequences for treatment allocation, response
and clinical outcome. For example, we have reported previously
that HR+HER2− patients who are reclassiﬁed into Basal-type by
the 80-gene signature (80-GS) have a substantially higher rate of
pathologic complete response (pCR) to neoadjuvant chemother-
apy compared to HR+HER2−/Luminal patients (32% vs. 5%).7 A
contributor to molecular reclassiﬁcation of estrogen receptor (ER)
positive tumors might be ER borderline positivity by immunohis-
tochemistry (IHC), i.e., 1–9% positive cells, since it has been shown
that those tumors mainly cluster with Basal-type tumors by gene-
expression proﬁling.8,9 However, molecular subtyping will also
identify a group of clearly ER-positive patients (by IHC and/or
mRNA) that fail to elicit the estrogen-induced transcriptional
responses.
A possible explanation is the inability of IHC and/or mRNA to
differentiate non-functional from functional ER in those patients.
Several ERα variants have been described in human breast cancers
and in normal tissues expressing ERα, most of them being mRNA
exon skipping splicing variants.10–12 The activity of these variants
has been investigated in multiple functional studies, i.e., they can
be functionally negative, dominant negative or dominant active
on ERα target genes.10 Two splice variants (ERΔ3 and ERΔ7) have
been described as dominant negative forms in the presence of
wild-type ERα, indicating that they also inhibit the function of
wild-type ERα.10,13 More recently, a third variant with dominant
negative activity has been reported, named ERα-36 (referring to
the protein molecular weight of 36 kDa).14 We have shown
previously in a small case-control study that ER+/Basal tumors
have relatively high levels of the dominant-negative ERΔ7 splice
variant, although consequences for response to adjuvant therapy
and clinical outcome were unknown in those cases.15
In the present study, we have examined the expression of total
ER and ER variants mRNA in ER+/Basal breast cancer patients
enrolled in the prospective neoadjuvant NBRST registry trial
(NCT01479101) and compared these expression values to patients
with ER+/Luminal B breast cancer. We also report pathological
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complete response rates to neoadjuvant therapy and 3-year
follow-up data for both patient groups within the NBRST trial and
compared those to ER−/Basal breast cancer patients.
RESULTS
Clinical and molecular subtyping
A total of 1072 eligible patients were enrolled in the NBRST study,
of which 694 (64.7%) patients were classiﬁed as ER-positive based
on IHC (deﬁned as ≥1% ER+ cells). The 80-gene molecular
subtyping signature (BluePrint, Agendia) classiﬁed 514/694
(74.1%) ER-positive patients as Luminal-type, 91/694 (13.1%) ER-
positive patients as Basal-type and 89/694 (12.8%) ER-positive
patients as HER2-type, of which 86/89 (96.6%) were HER2-positive
by IHC/FISH. MammaPrint, a 70-gene risk of recurrence signature,
deﬁned all 91 ER+/Basal patients at high-risk for disease
recurrence. In contrast, the frequency of MammaPrint high-risk
classiﬁcation among 514 ER+/Luminal patients was 66.9% (i.e.,
Luminal B) (P < 0.001; Table 1).16 Both subgroups of ER+/Basal and
ER+/Luminal B patients had a broad range of percentage positive
staining for ER by IHC ranging from 1–99% for ER+/Basal and
1–100% for ER+/Luminal B patients, albeit a signiﬁcant difference
in the mean percentage positive ER staining was found (87.6% for
ER+/Luminal B vs. 22.1% for ER+/Basal, P < 0.001; Table 1).16 The
frequency of ER borderline tumors (1–9% positive cells by IHC)
was 44.0% for ER+/Basal tumors and 1.2% for ER+/Luminal B
tumors (P < 0.001; Table 1).16 The difference in ER staining was
reﬂected in a signiﬁcant difference in the percentage of PR-
positive tumors between the two groups (85.2% for ER+/Luminal
B vs. 29.7% for ER+/Basal, P < 0.001; Table 1) and the mean
percentage PR positivity in PR-positive tumors (58.1% for
ER+/Luminal B vs. 10.9% for ER+/Basal, P < 0.001; Table 1).16 This
ﬁnding is consistent with PR expression being controlled
transcriptionally, at least in part, by ER.
Total ERα and ERα variant mRNA qPCR analysis
Total ERα mRNA expression measured by qPCR was signiﬁcantly
lower for ER+/Basal tumors compared to a control group of
ER+/Luminal B tumors (P < 0.001; Fig. 1).16 Interestingly, the levels
of total ERα mRNA for ER+/Luminal B tumors were similar to total
ERα mRNA expression in the control group of normal breast
tissues (P= 0.97; Fig. 1).16
Figure 2 illustrates the relationship between total ERα mRNA
expression and the percentage of ER positivity by IHC.16
Interestingly, most ER+/Basal tumors showed relatively low total
ERα mRNA expression, even in cases of high percentage positive
Table 1. ER/PR positivity and HER2 status in ER-positive tumors (IHC ≥1%) in NBRST (N= 694)
80-GS Luminal A
(N= 170)
80-GS Luminal B
(N= 344)
80-GS Basal
(N= 91)
80-GS HER2
(N= 89)
ER positivity
Mean % staining 88.4% 87.6% 22.1% 60.0%
Range (min,max) 1,100% 1,100% 1,99% 1,100%
IQRa (Q1-Q3) 90–99% 85–99% 4–29% 20–90%
% ER borderlineb 2.9% 1.2% 44.0% 15.7%
PR status
Positive (≥1% IHC) 96.5% 86.6% 29.7% 62.9%
Mean % stainingc 76.8% 58.1% 10.9% 31.6%
Range (min,max) 1,100% 1,100% 1,50% 1,100%
IQRa (Q1-Q3) 70–98% 28–90% 2–9% 5–51%
% HER2 positive
(IHC/FISH)
10.6% 19.5% 16.5% 96.6%
aIQR, interquartile range
bdeﬁned as 1–9% positive cells by IHC
cmean % staining in PR-positive tumors
ER+/Basal
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Fig. 1 Normalized total ERalpha mRNA expression. Box plots
showing normalized total ERalpha mRNA expression for ER+/Basal
tumors (N= 81, blue box), ER+/Luminal B tumors (N= 48, orange
box) and normal breast tissues (N= 8, gray box). Central line in
boxes represent median value, boundaries of boxes represent the
interquartile range and ends of whiskers represent the minimum
and maximum values. P-values are obtained using the
Mann–Whitney test
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staining by IHC. In contrast, ER+/Luminal B tumors showed
relatively high total ERα mRNA expression, even in borderline
(deﬁned as ER 1–9% by IHC) or low (deﬁned as ER <50% by IHC) ER
expressing tumors (Fig. 2).16
Expression of dominant negative ERα variants (ERΔ3, ERΔ7, and
ERα-36) was measured by variant-speciﬁc quantitative real-time
PCR. It should be noted that the ERα-36 variant could only be
reliably measured in cDNA from fresh frozen RNA samples
because of the low mRNA expression of this variant, which was
below the detection limit in transcribed cDNA from most FFPE
RNA samples. As shown in Supplemental Fig. 1, the ERΔ7 variant
was the highest expressed variant in both ER+/Basal tumors (Fig.
S1A-B), as well as ER+/Luminal B (Fig. S1C-D) and normal breast
(Fig. S1E).16 The absolute expression of ERΔ7 was lower in
ER+/Basal tumors compared to ER+/Luminal B tumors. However,
the expression of ERΔ7 relative to total ERα mRNA was
signiﬁcantly increased in ER+/Basal tumors compared to
ER+/Luminal B tumors (P < 0.001; Fig. 3a).16 This difference in
relative ERΔ7 expression was present in the complete group of
tumors with ER ≥1% by IHC (Fig. 1a), as well as in the subgroup of
tumors with ER ≥10% by IHC (Fig. 3b).16 The expression of ERΔ3
and ERα-36 relative to total ERα mRNA was much lower (ratio
<0.05) than the relative ERΔ7 expression and not signiﬁcantly
different between ER+/Basal and ER+/Luminal B tumors. The
relative expression of ERΔ3 is shown in Supplementary Fig. 2, for
ERα-36 the relative expression was even lower and only
measurable in fresh frozen samples (data not shown).16
Treatment response and outcome
To compare treatment response and outcome across molecular
subtypes, only HER2− patients with known ER status, 80-GS
subtype, and follow-up were evaluated (N= 667). The majority of
these HER2− patients were ER-positive by IHC (65.7%). The 80-GS
and MammaPrint classiﬁed 130 ER-positive patients (29.7%) as
Luminal A (low risk of recurrence), 238 ER-positive patients (54.3%)
as Luminal B (high risk of recurrence) and 70 ER-positive patients
(16.0%) as Basal-type. All 229 ER-negative patients were classiﬁed
as Basal-type. The majority of these patients received neoadjuvant
chemotherapy (610/667; 91.5%), whereas a small group of patients
received neoadjuvant hormonal therapy (57/667; 8.5%). Following
neoadjuvant treatment, 34.3% (24/70) of ER+/Basal patients had
achieved a pathological complete response (pCR), similar to 37.6%
(86/229) of ER−/Basal patients, and much higher than 5.9% (14/
238) of ER+/Luminal B or 2.3% (3/130) of ER+/Luminal A patients.
All patients with pCR received neoadjuvant chemotherapy. Subset
analysis ER+/Basal patients showed a non-signiﬁcant difference in
pCR rate between PR-negative patients (N= 53, 39.6% pCR) and
PR-positive patients (N= 17, 17.6% pCR) (P= 0.14).
To evaluate long-term response, 583 patients from this subset
reported follow-up with a median of 34 months (range
0.3–77 months). Clinical characteristics and outcome are shown
in Table 2.16 The 3-year distant metastasis free interval (DMFI) for
ER+/Basal patients was 65.8% (95%CI: 53.3–81.3), compared to
76.7% (95%CI: 70.5–83.5) for ER−/Basal patients (Table 2; Fig. 4a).16
ER+/Luminal patients had a substantially better 3-year DMFI:
88.9% (95%CI: 84.2–93.8) for ER+/Luminal B and 96.3% (95%CI:
92.3–100) for ER+/Luminal A patients (Table 2; Fig. 4a).16 A large
proportion of Basal-type patients had a DMFI event in 3-years: 18
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Fig. 2 Correlation between percentage ER staining by immunohis-
tochemistry and normalized total ERalpha mRNA expression.
Distribution plot showing the correlation between percentage ER
staining by immunohistochemistry and normalized total ERalpha
mRNA expression for ER+/Basal tumors (N= 81, blue dots) and
ER+/Luminal B tumors (N= 48, orange dots). FF fresh frozen
samples; FFPE formalin-ﬁxed parafﬁn embedded samples
ER+/Basal
FF (N=18)
ER+/Luminal-B 
FF (N=8)
Normal breast 
FF (N=8)
ER+/Basal 
FFPE (N=63)
ER+/Luminal-B 
FFPE (N=40)
0.0
0.2
0.4
0.6
0.8
1.0
R
at
io
 E
R
Δ
7/
to
ta
l E
R
α
 
m
R
N
A
Ratio ERΔ7/total ERα 
P = .0116 P < .0001P = .85
ER+/Basal 
FF (N=11)
ER+/Luminal-B
FF (N=8)
Normal breast 
FF (N=8)
ER+/Basal
FFPE (N=38)
ER+/Luminal-B 
FFPE (N=36)
0.0
0.2
0.4
0.6
0.8
1.0
R
at
io
 E
R
Δ
7/
to
ta
l E
R
α
 
m
R
N
A
Ratio ERΔ7/total ERα in ER ≥10% IHC cases
P = .0951 P = .78 P < .0001
a
b
Fig. 3 Ratio of ERΔ7 mRNA expression and total ERalpha mRNA
expression. Box plots showing ratio of ERΔ7 mRNA expression and
total ERalpha mRNA expression for ER+/Basal tumors (blue boxes),
ER+/Luminal B tumors (orange boxes) and normal breast tissues
(gray box). Ratio’s for fresh frozen (FF) samples and formalin-ﬁxed
parafﬁn embedded (FFPE) samples are depicted in separate
boxplots. Central line in boxes represent the median value,
boundaries of boxes represent the interquartile range and ends of
whiskers represent the minimum and maximum values. P-values are
obtained using the Mann-Whitney test. a Box plots for all ER+/Basal
and ER+/Luminal B tumors. b Box plots for subgroup of ER+/Basal
and ER+/Luminal B tumors with ER-positivity of ≥10% by
immunohistochemistry
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Table 2. Clinical characteristics of HER2-negative patients in NBRST study with follow-up (N= 538)
All ER+/Luminal A ER+/Luminal B ER+/Basal ER−/Basal
(N= 583) (N= 118) (N= 213) (N= 54) (N= 198)
Age
<35 40 (6.9%) 3 (2.5%) 14 (6.6%) 8 (14.8%) 15 (7.6%)
35–50 208 (35.7%) 41 (34.7%) 68 (31.9%) 20 (37.0%) 79 (39.9)
51–70 287 (59.2%) 56 (47.5%) 111 (52.1%) 22 (40.7%) 98 (49.5%)
>70 48 (8.2%) 18 (15.3%) 20 (9.4%) 4 (7.4%) 6 (3.0%)
Ethnicity
African/black 82 (14.1%) 8 (6.8%) 32 (15.0%) 5 (9.3%) 37 (18.7%)
Asian 12 (2.1%) 2 (1.7%) 7 (3.3%) 2 (3.7%) 1 (0.5%)
Caucasion/white 428 (73.4%) 101 (85.6%) 149 (70.0%) 42 (77.8%) 136 (68.7%)
Hispanic 52 (8.9%) 6 (5.1%) 22 (10.3%) 3 (5.6%) 21 (10.6%)
Mixed 4 (0.7%) 1 (0.8%) – 1 (1.9%) 2 (1.0%)
Native America 2 (0.4%) – 2 (0.9%) – –
Other 3 (0.5%) – 1 (0.5%) 1 (1.9%) 1 (1.0%)
Menopausal status
Post-menopausal 330 (56.6%) 74 (62.7%) 125 (58.7%) 24 (44.4%) 107 (54.0%)
Premenopausal and perimenopausal 247 (42.4%) 43 (36.4%) 88 (41.3%) 30 (55.6%) 86 (43.4%)
Unknown 6 (1.1%) 1 (0.8%) – – 5 (2.5%)
cT stage
cT1 81 (13.9%) 14 (11.9%) 23 (10.8%) 6 (11.1%) 38 (19.2%)
cT2 331 (56.8%) 66 (55.9%) 119 (55.9%) 33 (61.1%) 113 (57.1%)
cT3 139 (23.7%) 34 (28.8%) 58 (27.2%) 10 (18.5%) 37 (18.7%)
cT4 31 (5.3%) 4 (3.4%) 12 (5.6%) 5 (9.3%) 10 (5.1%)
cTx 1 (0.2%) – 1 (0.5%) – –
cN stage
cN0 230 (39.5%) 59 (50.0%) 61 (28.6%) 22 (40.7%) 88 (44.4%)
cN1 268 (46.0%) 42 (35.6%) 117 (54.9%) 23 (42.6%) 86 (43.4%)
cN2 41 (7.0%) 6 (5.1%) 21 (9.9%) 4 (7.4%) 10 (5.1%)
cN3 14 (2.4%) 2 (1.7%) 3 (1.4%) 3 (5.6%) 6 (3.0%)
cNx 30 (5.1%) 9 (7.6%) 11 (5.2%) 2 (3.7%) 8 (4.0%)
Histological subtype
Invasive carcinoma NST 489 (83.9%) 80 (67.8%) 170 (79.8%) 53 (98.1%) 186 (93.9%)
Invasive lobular carcinoma 63 (10.8%) 31 (26.3%) 25 (11.7%) 1 (1.9%) 6 (3.1%)
Mixed subtype 17 (2.9%) 4 (3.4%) 11 (5.2%) – 2 (1.0%)
Other 14 (2.4%) 3 (2.5%) 7 (3.3%) – 4 (2.0%)
Histological grade
Grade 1 51 (8.7%) 31 (26.3%) 16 (7.5%) 1 (1.9%) 3 (1.5%)
Grade 2 193 (33.1%) 63 (53.4%) 96 (45.1%) 5 (9.3%) 29 (14.6%)
Grade 3 316 (54.2%) 16 (13.6%) 87 (40.8%) 48 (88.9%) 165 (83.3%)
N/A 23 (3.9%) 8 (6.8%) 14 (6.6%) – 1 (0.5%)
MammaPrint genomic risk
Low-risk 118 (20.2%) 118 (100%) – – –
High-risk 465 (79.7%) – 213 (100%) 54 (100%) 198 (100%)
Neoadjuvant therapy
Chemotherapy 525 (90.1%) 80 (67.8%) 195 (91.5%) 53 (98.1%) 197 (99.5%)
Endocrine therapy 49 (9.3%) 34 (28.8%) 15 (7.0%) – –
N/A 9 (1.5%) 4 (3.4%) 3 (1.4%) 1 (1.9%) 1 (0.5%)
Adjuvant therapy
Endocrine therapy 329 (56.4%) 102 (86.4%) 180 (84.5%) 32 (59.3%) 15 (7.6%)
None 254 (43.6%) 16 (13.6%) 33 (15.5%) 22 (40.7%) 183 (92.4%)
% DMFI at 3-years 96.3% 88.9% 65.8% 76.7%
(95% CI) (92.3–100) (81.2–93.8) (53.3–81.3) (70.5–83.5)
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events in 54 ER+/Basal patients (33.3%) and 46 events in 198
ER−/Basal patients (23.2%). In contrast, there were 35 DMFI events
in 213 ER+/Luminal B patients (16.4%) and 4 events in 118
ER+/Luminal A patients (3.4%). Of interest, all events in the
ER+/Basal patients occurred before 4-years and mirrors the
recurrence proﬁle of ER−/Basal tumors as compared to Luminal
B tumors where events are known to occur in years 5–10. Overall,
there was a signiﬁcant difference in DMFI survival between the
ER+/Basal, ER−/Basal, ER+/Luminal B and ER+/Luminal A patients
(log-rank P < 0.001; Fig. 4a).16 Subgroup analysis for ER+/Basal
patients as compared to ER+/Luminal B patients showed a
signiﬁcant difference in DMFI survival (P= .002).
Subset analysis of ER+/Basal patients showed a non-signiﬁcant
difference in DMFI between PR-negative patients and PR-positive
patients (Supplementary Fig. 3A, log-rank P= 0.08).16 Of note, PR-
positive patients had worse DMFI than PR-negative patients in this
subset as compared to the overall cohort where PR-positive patients
are commonly Luminal-type and have a better DMFI than PR-
negative patients (Supplementary Fig. 3B, log-rank P= 0.03).16 This
apparent contradiction can be explained by the higher pCR rate for
PR-negative patients in the ER+/Basal cohort. Basal-type patients
who achieved a pCR exhibited signiﬁcantly better 3-year probability
of DMFI compared to those with residual disease (RD), regardless of
ER status (log-rank P < 0.001; Fig. 4b).16 The 3-year DMFI for ER
+/Basal patients with pCR was 78% (95% CI: 54.6–100%) compared
to 61% (95% CI: 47.1–79.7%) for ER+/Basal patients with RD.
DISCUSSION
The question of whether a breast cancer is ER-positive and
endocrine responsive has been an ongoing debate since the
outset of endocrine therapy. Discordant ER status by immunohis-
tochemistry and molecular subtype may arise from borderline ER
expression (degree of positivity)8, testing artefacts resulting in
inaccurate ER status determination6,17 or it may indicate the
expression of a non-functional estrogen receptor. Gene signatures
may help to resolve these uncertainties and more reliably and
robustly classify patients based on activity within the molecular
pathways. In the end biology matters, and it is more than just
expression of ER.
To explain discordant clinical and molecular subtyping, we
assessed 80-GS molecular subtype, total ER mRNA expression and
ER variant mRNA expression in 84 ER+/Basal and 48 ER+/Luminal
B breast cancers in a prospective trial (NBRST registry trial). We did
not include ER−/Basal breast cancers for this analysis, since ER
mRNA expression in those tumors is usually below the limit of
detection. We asked whether molecular reclassiﬁcation was
associated with the level of total ER mRNA and expression of
dominant-negative estrogen receptor variants. ER-positive
patients, reclassiﬁed by the 80-gene signature as molecularly
Basal-type, had signiﬁcantly lower total ER expression by IHC and
mRNA compared to a control group of ER+/Luminal B patients.
We showed that expression of the ERΔ7 splice variant relative to
total ER mRNA is signiﬁcantly increased in ER+/Basal patients
compared to ER+/Luminal B patients. This difference was present
in both borderline ER-positive tumors (1–9% IHC) and ER-positive
tumors with higher ER expression (≥10% IHC, up to 99%). This
observation is in concordance with our previous report which was
based on a much smaller and more heterogeneous retrospective
cohort of ER+/Basal patients without clinical follow-up.15 The
combination of low ER mRNA expression and high relative ERΔ7
variant expression provides a rationale why these are classiﬁed as
Basal-type, but would not have been identiﬁed as ER-IHC negative
(as illustrated in Fig. 4 of ref. 15).15
Interestingly, the 80-GS used in this study to classify patients as
molecular Luminal-type, Basal-type or HER2-type was developed
using IHC status as a guide.18 Although supervised by standard HR
and HER2 IHC status, the genes comprising each molecular
subtype proﬁle were identiﬁed as the most differentially regulated
between clinical subtypes, offering a different level of granularity.
Currently, no ‘gold standard’ for molecular subtyping of breast
cancer has been deﬁned and, although overlap exists, different
gene sets are used in each classiﬁer.19 Of the 80 genes in the 80-
GS, 13 of 28 reporter genes used to classify tumors as Basal-type
(46.4%) overlap with genes present in the intrinsic gene set
reported by Perou et al.4,18 The 80-GS gene set used for molecular
subtyping has only 4 genes in common with the MammaPrint
gene set used for assessing risk of recurrence (2 genes in the
Basal-subtype and 2 genes in the Luminal-subtype). Recently, it
was reported within the I-SPY 2 trial that ER+/80-GS Basal-type
tumors have higher expression of basal-type keratins (keratins 5/
14/17) compared with ER+/Luminal-type tumors.20 This supports
the ﬁnding of Cheang et al. who identiﬁed EGFR and cytokeratin
5/6 expression by immunohistochemistry as prognostic markers
for basal-like breast cancers.21
ERΔ7 was the highest expressed variant among those tested,
which is in line with previous observations.13 We found very low
mRNA expression values of the ER variant ERα-36, which has been
described as a mediator of the ER non-genomic signaling
pathway.14 This partly conﬂicts with a previous study reporting,
based on ERα-36 protein expression using a custom antibody,
high expression of this variant in a signiﬁcant subset of ER-positive
breast cancers.22
We also compared total ER mRNA expression of ER+/Basal and
ER+/Luminal B tumors with an external control group of normal
Fig. 4 Kaplan Meier curves showing distant metastasis free interval
(DMFI). Kaplan Meier curves showing distant metastasis free interval
(DMFI) for HER2-negative patients in NBRST study with follow-up
(N= 538). P-values are obtained using the log-rank test. a DMFI for
all patients stratiﬁed by ER status and molecular subtyping. b DMFI
of Basal patients (N= 252) stratiﬁed by ER status and response to
neoadjuvant therapy (pCR pathological complete response or RD
residual disease)
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breast tissues from patients with concurrent breast cancer. We
strikingly found that ER mRNA expression levels of ER+/Luminal B
tumors are comparable to normal breast epithelium. However, the
normal breast group is relatively small and unmatched. Future
work studying ER mRNA expression in a larger cohort of matched
normal tissues at the time of tumor detection is necessary to
investigate the relationship between ER mRNA expression in
normal breast and tumor subtypes.
This study has some limitations. First, clinical subtyping by IHC/
FISH analysis was performed in local pathology laboratories
according to their pre-existing protocols, which may have
contributed to interinstitutional differences in assessment and
classiﬁcation. This, and the fact that the NBRST neoadjuvant trial is
enriched for high-risk patients, might explain the higher frequency
of molecular reclassiﬁcation of ER+ HER2− tumors in our study
compared to what has been reported for adjuvant studies with
centrally assessed IHC/FISH subtypes. The prospective, rando-
mized phase III MINDACT study used centrally assessed IHC/FISH
subtypes and found that 99/4718 (2.1%) ER-positive (IHC ≥1%)
patients were reclassiﬁed as Basal-type by the 80-GS.5 This
percentage is in line with what we have reported previously as
discordancy rate between mRNA based ER classiﬁcation and
molecular subtyping.15 Iwamoto et al. reported that 29 out 465
(6.2%) ER-positive (IHC ≥1%) patients were classiﬁed as Basal-type
by PAM50 and 17 (58.6%) of them had ER ≥10%.8 However,
compared to central IHC testing, local assessment of ER status by
IHC better reﬂects how testing for ER is performed in routine
clinical practice. Furthermore, the reclassiﬁcation frequency in
NBRST is comparable to the recently reported reclassiﬁcation
frequency in the multicenter phase II neoadjuvant I-SPY 2 trial. In
this trial, the 80-GS was applied to 375 ER+/HER2− patients and
29% of patients were classiﬁed as Basal-type.20 The frequency of
molecular reclassiﬁcation of ER IHC-positive cases to Basal-type by
80-GS was evaluated by site to assess if there was a site
dependence. We found that 31 different sites contributed to this
subset of patients, most with only 1 or 2 patients each. The 10
institutions who contributed more ER+/Basal patients also
enrolled a higher proportion of patients to the study overall,
indicating that there was not a bias in IHC quality. Some
institutions used both local and national laboratories to process
the IHC, and all institutions used one of the two commonly used
monoclonal, commercially available antibodies (Ventana SP-1 and
Leica 6F11). The Ventana SP-1 clone is raised against a synthetic
peptide that corresponds to the C-terminal domain of the ER
alpha molecule (Ventana antibody datasheet). This antibody will,
beside wild-type ERalpha, most likely also recognize ERΔ3 but not
ERΔ7 since this variant leads to a truncated ER protein.15 The Leica
6F11 clone is raised against recombinant estrogen receptor alpha
protein (Leica antibody datasheet). It is unknown if this antibody
will recognize any of the ER variants.
Second, immunohistochemical assessment of ER was performed
in needle core biopsies taken before neoadjuvant treatment.
Although the reported concordance rate with surgical excision
specimens is high, but variable (80–99%), it may have contributed
to false positive staining.23 It has been shown that cases with large
tumor size (>2 cm) will more frequently have a change in
biomarker after neoadjuvant chemotherapy as a result of tumor
heterogeneity.24 The average tumor size in NBRST is much higher
than for example the MINDACT study (71.6% T1, e.g., <2 cm, in
MINDACT vs. 19.2% T1 in NBRST).
Third, the number of ER+/Basal patients in our study was relatively
small and the trial design created some heterogeneity in (neo)
adjuvant treatment strategies for these patients. Because of the
relatively low number of ER+/Basal patients, it will be difﬁcult to
design a prospective randomized clinical trial to deﬁne the optimal
treatment for this subgroup of patients. Long-term prognosis for
these patients is controversial. For borderline ER-positive patients,
some studies reported clinical outcomes similar to those of ER
negative cancers, and others showing an intermediate prognosis
compared to ER-negative and ER-positive tumors.8 In MINDACT, the
subgroup of ER+/Basal patients (N= 99) had a 5-year distant
metastasis free survival (DFMS) of 90.2% compared to 95.9% for
ER+/Luminal-type patients, although this difference was not
statistically signiﬁcant.5 We report a substantially higher rate of pCR
to neoadjuvant chemotherapy for this subgroup of ER+HER2−/Basal
patients compared to HR+HER2−/Luminal patients (34 vs. 5%),
indicating the presence of underlying differences in biology between
these subgroups.7 The high pCR rate of ER+/HER2−/Basal patients
was recently conﬁrmed in the I-SPY 2 trial.20 Our preliminary 3-year
DMFI analysis also supports that the long-term outcome of these ER
+/Basal patients is in-line with clinically Basal-type patients, both in
metastasis free survival and in the pattern of early events. Although it
is unclear if ER+/Basal tumors are responsive to endocrine therapy, a
potential beneﬁt from empirical adjuvant endocrine therapy cannot
be excluded in this subgroup of patients. Of signiﬁcant practical
impact, we have identiﬁed by genomic proﬁling a group within
clinically ER-positive patients who exhibit a signiﬁcantly improved
response to neoadjuvant chemotherapy (i.e., Basal-type) while also
identifying the patients who do likely not beneﬁt from neoadjuvant
chemotherapy (i.e., Luminal-type). The issue becomes how the
treatment of high-risk Basal patients, irrespective of ER status, would
be different from high-risk Luminal patients in both the neoadjuvant
and adjuvant setting. In clinical practice, the chemotherapy regimens
are more often considered differently based on (molecular) subtype
and future studies are needed to speciﬁcally address this question.
Finally, our study provides a rationale why ER+/Basal breast cancers
are transcriptionally ER-negative.
METHODS
Patient selection NBRST registry trial
The prospective NBRST registry trial (ClinicalTrials.gov identiﬁer
NCT01479101) enrolled 1072 breast cancer patients from 64 US institutions
between June 2011 and December 2014. NBRST was conducted as an
observational, case-only study and exploratory in nature, therefore a
sample size calculation was not applied as only descriptive statistics were
pre-planned. Patients received either neoadjuvant chemotherapy (NCT) or
neoadjuvant hormonal therapy (NHT) after successful BluePrint molecular
subtyping and MammaPrint genomic risk stratiﬁcation (Agendia Inc).
Selection of neoadjuvant and adjuvant treatment regimen was at the
discretion of physicians and no speciﬁc recommendations were given. The
trial was approved by Institutional Review Boards in all participating
institutions. Clinical data collection and consent for use of tissue for future
scientiﬁc research was obtained by written informed consent.
Clinical and molecular subtyping
Hormone receptor status was locally assessed on pretreatment core
biopsies using immunohistochemistry for estrogen receptor (ER) and
progesterone receptor (PR). In accordance with the joint ASCO/ACP
guideline, both ER and PR were considered positive if these was ≥1%
tumor cells with positive nuclear staining.1 HER2 status was locally
assessed by immunohistochemistry and/or ﬂuorescence in situ hybridiza-
tion (FISH). HER2 status was regarded as positive if there was 3+ staining
and/or FISH positivity.
Molecular subtyping was performed using the 80-gene molecular
signature BluePrint (Agendia Inc.) in a centralized laboratory on RNA
isolated from pretreatment fresh frozen or formalin-ﬁxed core needle
biopsies. Genomic risk assessment was performed on the same RNA
sample using the 70-gene molecular signature MammaPrint (Agendia Inc),
that stratiﬁed patients at low or high risk for disease recurrence. Both
assays are microarray based and speciﬁc procedures has been described
before.18,25
Variant speciﬁc quantitative real-time PCR (qPCR)
ERα variant speciﬁc primer pairs were designed in which the reverse
primer was located across the splice site (ERΔ3 and ERΔ7) or in a variant
speciﬁc exon (ERα-36). For total ERα mRNA, an intron-spanning primer pair
was designed in which the forward primer was located in exon 1 and the
F.H. Groenendijk et al.
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reverse primer in exon 2. Primer sequences are shown in Supplementary
Table 1.16 Speciﬁcity of the primer pairs was tested using cDNA from MCF7
breast cancer cells overexpressing either wild-type or variant ERα.
cDNA was synthesized for all samples in two independent reactions
each using 500 ng RNA (fresh frozen samples), 800 ng RNA (FFPE samples)
or 125 ng RNA (fresh frozen normal breast controls) using SuperScript IV
reverse transcriptase (ThermoFisher) with random hexamers following
manufacturer’s protocol (50 min reaction time). qPCR reactions were
performed in technical triplicates using PowerUp SYBR Green (Thermo-
Fisher) master mix in a 15 ul reaction with 0.8 ul 10 μM primermix and 5 μl
diluted cDNA. qPCR reactions were performed using the 7500 Fast system
(Applied Biosystems) and analyzed using the 7500 Software v2.3 (Applied
Biosystems). Expression levels were calibrated and quantiﬁed using a
reference standard dilution curve (7-fold log10 concentration range) from a
synthetic qPCR template containing the sequence template for all the
reactions (gBlock, Integrated DNA Technologies). Two internal reference
genes were used for normalization (GAPDH and Actin-B). The relative
expression of ERα variants was calculated by dividing the variant mRNA
expression by the total ERα mRNA expression.
Sample selection ERα variant analysis
In the NBRST study, RNA was available from 84 out of 91 ER-positive Basal-
type tumors (Fresh Frozen N= 18, FFPE N= 66) for quantiﬁcation of total
ERα mRNA and ERα variant mRNA by qPCR. All 84 cases were classiﬁed by
MammaPrint as high-risk. RNA from 3 cases was of too low quality for
successful ER variant analysis. For comparison, we selected from the NBRST
study 48 ER-positive, MammaPrint high-risk Luminal-type (i.e., Luminal B)
tumors with a broad range of ER-positivity by IHC (range 1–100%) for
which RNA was available (Fresh Frozen sampes N= 8, FFPE samples N=
40). As a second control group, we used an external set of 8 fresh frozen
RNAs isolated from histologically veriﬁed normal breast tissue from 7
patients (range 40–72 years) with concurrent breast cancer (Erasmus MC,
Rotterdam, The Netherlands).
Treatment response and outcome
Response to treatment was collected in institutionally approved case
report forms (CRF) following deﬁnitive surgery after completing neoadju-
vant therapy, and then again 2–3 years and 5 years after surgery.
Pathological complete response (pCR) was used as the primary endpoint to
assess response to the neoadjuvant treatment regimen, deﬁned as the
absence of invasive carcinoma in both the breast and axilla at microscopic
examination of the resection specimen, regardless of the presence of
carcinoma in situ (ypT0/TisN0).26 Distant metastasis free interval (DMFI)
was used as the primary endpoint for long-term follow-up, deﬁned as time
from diagnosis to distant metastasis or time of breast cancer-related or
unknown cause of death.27
Statistical analysis
Data analysis and statistics were performed using Prism 7 software.
Differences between groups were compared using the Mann–Whitney test
(2-sided p-value). Kaplan–Meier survival analysis and log-rank statistics
were performed in R version 3.4.0.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
DATA AVAILABILITY
The clinical and expression analysis data ﬁles generated and analyzed during this
study are available in the following data record: https://doi.org/10.6084/m9.
ﬁgshare.7855742.16 The data record also includes a description of data ﬁles not
available in the ﬁgshare repository, along with relevant data access requirements. As
outlined in the data record, certain data ﬁles supporting this analysis are available on
request only; raw array data have not been made publicly available as part of a
collaboration agreement with the diagnostic company Agendia Inc.
ACKNOWLEDGEMENTS
We are grateful to all women who participated in this study, all the investigators,
surgeons, pathologists, and research nurses. The prospective NBRST registry trial
(NCT01479101) is sponsored by Agendia Inc.
AUTHOR CONTRIBUTIONS
Conception and study design: F.G., R.B., P.W.; Acquisition of data: F.G., T.T., E.Y.;
Analysis and interpretation of data: F.G., T.T., E.Y.; Drafting of manuscript: F.G., T.T., E.
Y.; Critical revision of manuscript: all authors; Statistical analysis: F.G., T.T.; Supervision:
F.G., W.D., R.B., P.W.
ADDITIONAL INFORMATION
Supplementary information accompanies the paper on the npj Breast Cancer
website (https://doi.org/10.1038/s41523-019-0109-7).
Competing interests: T.T., E.Y., W.A. and R.B. are employees of Agendia Inc. The
remaining authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
REFERENCES
1. Hammond, M. E. et al. American Society of Clinical Oncology/College Of Amer-
ican Pathologists guideline recommendations for immunohistochemical testing
of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28,
2784–2795 (2010).
2. Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast
cancer: American Society of Clinical Oncology/College of American Pathologists
Clinical Practice Guideline Focused Update. J. Clin. Oncol. 36, 2105–2122 (2018).
3. Weigelt, B., Baehner, F. L. & Reis-Filho, J. S. The contribution of gene expression
proﬁling to breast cancer classiﬁcation, prognostication and prediction: a retro-
spective of the last decade. J. Pathol. 220, 263–280 (2010).
4. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406,
747–752 (2000).
5. Viale, G. et al. Immunohistochemical versus molecular (BluePrint and Mamma-
Print) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG
3-04 MINDACT trial. Breast Cancer Res. Treat. 167, 123–131 (2018).
6. Li, Q. et al. Minimising immunohistochemical false negative ER classiﬁcation
using a complementary 23 gene expression signature of ER status. PLoS ONE 5,
e15031 (2010).
7. Whitworth, P. et al. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal
Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony
Trial (NBRST) Predicted by Molecular Subtyping. Ann. Surg. Oncol. 24, 669–675
(2017).
8. Iwamoto, T. et al. Estrogen receptor (ER) mRNA and ER-related gene expression in
breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J. Clin.
Oncol. 30, 729–734 (2012).
9. Deyarmin, B. et al. Effect of ASCO/CAP guidelines for determining ER status on
molecular subtype. Ann. Surg. Oncol. 20, 87–93 (2013).
10. Taylor, S. E., Martin-Hirsch, P. L. & Martin, F. L. Oestrogen receptor splice variants
in the pathogenesis of disease. Cancer Lett. 288, 133–148 (2010).
11. Leygue, E. R., Watson, P. H. & Murphy, L. C. Estrogen receptor variants in normal
human mammary tissue. J. Natl Cancer Inst. 88, 284–290 (1996).
12. Pfeffer, U., Fecarotta, E. & Vidali, G. Coexpression of multiple estrogen receptor
variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7
cells. Cancer Res. 55, 2158–2165 (1995).
13. Garcia Pedrero, J. M., Zuazua, P., Martinez-Campa, C., Lazo, P. S. & Ramos, S. The
naturally occurring variant of estrogen receptor (ER) ERDeltaE7 suppresses
estrogen-dependent transcriptional activation by both wild-type ERalpha and
ERbeta. Endocrinology 144, 2967–2976 (2003).
14. Wang, Z. et al. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction
of estrogen- and antiestrogen-dependent membrane-initiated mitogenic sig-
naling. Proc. Natl Acad. Sci. USA 103, 9063–9068 (2006).
15. Groenendijk, F. H., Zwart, W., Floore, A., Akbari, S. & Bernards, R. Estrogen receptor
splice variants as a potential source of false-positive estrogen receptor status in
breast cancer diagnostics. Breast Cancer Res. Treat. 140, 475–484 (2013).
16. Groenendijk, F. H., et al. Clinical and expression data ﬁles supporting study into
molecular reclassiﬁcation from Luminal to Basal-type breast cancer and links with
expression of dominant-negative ER variants. ﬁgshare. https://doi.org/10.6084/
m9.ﬁgshare.7855742 (2019).
F.H. Groenendijk et al.
7
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2019)    15 
17. Rakha, E. A. et al. Low-estrogen receptor-positive breast cancer: the impact of
tissue sampling, choice of antibody, and molecular subtyping. J. Clin. Oncol. 30,
2929–2930 (2012).
18. Krijgsman, O. et al. A diagnostic gene proﬁle for molecular subtyping of breast cancer
associated with treatment response. Breast Cancer Res. Treat. 133, 37–47 (2012).
19. Rakha, E. A., Reis-Filho, J. S. & Ellis, I. O. Basal-like breast cancer: a critical review. J
Clin. Oncol. 26, 2568–2581 (2008).
20. van ‘t Veer, L. et al. BluePrint basal subtype predicts neoadjuvant therapy
response in ~400 h+ HER2− patients across 8 arms in the I-SPY 2 TRIAL. Eur. J.
Cancer 103SI, e15–e16 (2018).
21. Cheang, M. C. et al. Basal-like breast cancer deﬁned by ﬁve biomarkers has
superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14,
1368–1376 (2008).
22. Shi, L. et al. Expression of ER-{alpha}36, a novel variant of estrogen receptor
{alpha}, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol. 27,
3423–3429 (2009).
23. Dekker, T. J. et al. Reliability of core needle biopsy for determining ER and
HER2 status in breast cancer. Ann. Oncol. 24, 931–937 (2013).
24. Zhou, X. et al. Alterations of biomarker proﬁles after neoadjuvant chemotherapy
in breast cancer: tumor heterogeneity should be taken into consideration.
Oncotarget 6, 36894–36902 (2015).
25. Glas, A. M. et al. Converting a breast cancer microarray signature into a high-
throughput diagnostic test. BMC Genomics 7, 278 (2006).
26. Giuliano, A. E. et al. Breast cancer-major changes in the American joint committee
on cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 290–303
(2017).
27. Hudis, C. A. et al. Proposal for standardized deﬁnitions for efﬁcacy end points in
adjuvant breast cancer trials: the STEEP system. J. Clin. Oncol. 25, 2127–2132
(2007).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2019
F.H. Groenendijk et al.
8
npj Breast Cancer (2019)    15 Published in partnership with the Breast Cancer Research Foundation
